スタッフ紹介

助教澤田　憲太郎

Kentaro Sawada

助教　澤田　憲太郎

学歴

2003年3月
北海道釧路湖陵高等学校　卒業
2010年3月
北海道大学医学部医学科　卒業
2019年3月
北海道大学院医学研究科医学専攻　博士課程　修了

職務経歴

2010年4月
釧路労災病院　初期研修医
2012年4月
釧路労災病院　内科
2014年4月
北見赤十字病院　消化器内科
2015年4月
北海道大学病院　消化器内科　医員
2016年4月
国立がん研究センター東病院　消化管内科　がん専門修練医
2018年4月
北海道大学病院　腫瘍センター　医員
2019年4月
国立がん研究センター東病院　消化管内科　医員
2020年4月
釧路労災病院　腫瘍内科　部長
2026年4月1日
北海道大学病院　消化器内科　特任助教
2026年7月1日
北海道大学病院　消化器内科　助教

所属学会・資格

  • 日本内科学会 総合内科専門医
  • 日本臨床腫瘍学会 がん薬物療法専門医・指導医
  • 日本消化器病学会 消化器病専門医・指導医
  • 日本消化器内視鏡学会　専門医
  • 日本肝臓学会 専門医
  • 日本肉腫学会 専門医
  • 日本分子生物学会
  • 日本癌治療学会
  • 日本遺伝カウンセリング学会
  • 日本人類遺伝学会
  • European Society For Medical Oncology（ESMO）

受賞歴・研究助成歴

  • 2021年 Young Oncologist Travel Grants of ESMO congress

業績

論文

  1. Sawada K, Kotani D, Bando H.
    The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies.
    Front Oncol. 8:263. 2018.
  2. Sawada K, Nakamura Y, Yamanaka T, et al.
    Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer.
    Clin Colorectal Cancer. 17(3):198-205. 2018.
  3. Sawada K, Nakamura Y, Shitara K.
    Development of HER2-targeted Therapies for Gastrointestinal Cancer.
    European Oncology & Haematology. 16:29-38. 2020.
  4. Sawada K, Kotani D, Yukami H, et al.
    Definitive chemoradiotherapy has comparable survival outcomes to esophagectomy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: real-world data.
    Int J Clin Oncol. 27(8):1279-1288. 2022.
  5. Sawada K, Yamashita R, Sakai SA, et al.
    Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study.
    Cancer Res Commun. 5(5):857-870. 2025.
  6. Sogabe S, Tateno T, Yagisawa M, Ishikawa M, Sawada K, Muranaka T, Umemura M, Kato R, Takasaka T, Takahashi K, Dazai M, Iwanaga I, Oda H, Miyagishima T.
    Clinical impact of addition of bevacizumab to the first-line chemotherapy regimen in the treatment of patients with metastatic colorectal cancer.
    Gan To Kagaku Ryoho; 41: 1113-7. 2014.
  7. Muranaka T, Yuki S, Komatsu Y, Sawada K, Harada K, Kawamoto Y, Nakatsumi H, Sakamoto N.
    Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience.
    J Gastric Cancer; 16:177-181. 2016.
  8. Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, Yuki S, Kubota Y, Kubo K, Kawahata S, Kawakubo K, Kawakami H, Sakamoto N.
    Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
    J Gastrointest Oncol; 8:566-571. 2017.
  9. Kawamoto Y, Komatsu Y, Yuki S, Sawada K, Muranaka T, Harada K, Nakatsumi H, Fukushima H, Ishiguro A, Dazai M, Hatanaka K, Nakamura M, Iwanaga I, Uebayashi M, Sogabe S, Kobayashi Y, Miyagishima T, Ono K, Sakamoto N, Sakata Y.
    Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
    BMC Cancer; 17:837. 2017.
  10. Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, Muto M, Wakai T, Yamazaki K, Yasui W, Bando H, Fujimoto Y, Fukuoka S, Harano K, Kawazoe A, Kimura G, Koganemaru S, Kogawa T, Kotani D, Kuboki Y, Matsumoto H, Matsumoto S, Mishima S, Nakamura Y, Sawada K, Shingaki S, Shitara K, Umemoto K, Umemura S, Yasuda K, Yoshino T, Yamamoto N, Nishio K, Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association.
    Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0).
    Cancer Sci; 109(9):2980-2985. 2018.
  11. Nakamura Y, Sawada K, Fujii S, Yoshino T.
    HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer.
    ESMO Open; 4:e000530. 2019.
  12. Yagisawa M, Sawada K, Nakamura Y, Fujii S, Yuki S, Komatsu Y, Yoshino T, Sakamoto N, Taniguchi H.
    Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer.
    Clin Colorectal Cancer; S1533-0028(20)30156-0. 2020.
  13. Fujii S, Magliocco AM, Kim J, Okamoto W, Kim JE, Sawada K, Nakamura Y, Kopetz S, Park WY, Tsuchihara K, Kim TW, Raghav K, Yoshino T.
    International Harmonization of Provisional Diagnostic Criteria for ERBB2-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel.
    JCO Precis Oncol; 4.6-19. 2020.
  14. Kubota Y, Kawazoe A, Sasaki A, Mishima S, Sawada K, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Ishii G, Kuwata T, Shitara K.
    The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer.
    Clin Cancer Res; 26: 3784-3790. 2020.
  15. Sasaki A, Nakamura Y, Togashi Y, Kuno H, Hojo H, Kageyama S, Nakamura N, Takashima K, Kadota T, Yoda Y, Mishima S, Sawada K, Kotani D, Kawazoe A, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Yano T, Kobayashi T, Akimoto T, Nishikawa H, Shitara K.
    Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer.
    Gastric Cancer; 23:893-903. 2020.
  16. Ishii T, Kawazoe A, Sasaki A, Mishima S, Sawada K, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Kuwata T, Ishii G, Shitara K.
    Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer.
    Ther Adv Med Oncol; 12:1758835920942377. 2020.
  17. Sasaki A, Kawazoe A, Eto T, Okunaka M, Mishima S, Sawada K, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Akimoto T, Shitara K.
    Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer.
    ESMO Open; 4(Suppl 2):e000775. 2020.
  18. Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Sawada K, Taniguchi H, Fuse N, Nomura S, Fukui M, Matsuda S, Sakamoto Y, Uchigata H, Kitajima K, Kuramoto N, Asakawa T, Olsen S, Odegaard JI, Sato A, Fujii S, Ohtsu A, Yoshino T.
    Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.
    Nat Med; 27:1899-1903. 2021.
  19. Taniguchi H, Nakamura Y, Kotani D, Yukami H, Mishima S, Sawada K, Shirasu H, Ebi H, Yamanaka T, Aleshin A, Billings PR, Rabinowitz M, Oki E, Takemasa I, Kato T, Mori M, Yoshino T.
    CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
    Cancer Sci; 112:2915-2920. 2021.
  20. Kawamoto Y, Nakatsumi H, Harada K, Muranaka T, Ishiguro A, Kobayashi Y, Hayashi H, Yuki S, Sawada K, Yagisawa M, Nakano S, Sakamoto N, Komatsu Y.
    A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403).
    Oncologist; 26:e1675-e1682. 2021.
  21. Chida K, Kotani D, Masuishi T, Kawakami T, Kawamoto Y, Kato K, Fushiki K, Sawada K, Kumanishi R, Shirasu H, Matsubara Y, Yuki S, Komatsu Y, Yamazaki K, Yoshino T.
    The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
    Oncologist; 26:845-853. 2021.
  22. Sato D, Kadota T, Inaba A, Nishihara K, Takashima K, Nakajo K, Sawada K, Kotani D, Fujiwara H, Yoda Y, Kojima T, Fujita T, Fujii S, Yano T.
    Long-term clinical outcome after endoscopic resection of esophageal squamous cell carcinoma invading the muscularis mucosae without lymphovascular invasion.
    Gastrointest Endosc; 95:634-641.e3. 2022.
  23. Kawakami T, Masuishi T, Kawamoto Y, Go H, Kato K, Kumanishi R, Sawada K, Yuki S, Yamamoto K, Komatsu Y, Muro K, Fushiki K, Shirasu H, Yamazaki K.
    The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study.
    Cancer Med. 11:2184-2192. 2022.
  24. Ito K, Yuki S, Nakatsumi H, Kawamoto Y, Harada K, Nakano S, Saito R, Ando T, Sawada K, Yagisawa M, Ishiguro A, Dazai M, Iwanaga I, Hatanaka K, Sato A, Matsumoto R, Shindo Y, Tateyama M, Muranaka T, Katagiri M, Yokota I, Sakata Y, Sakamoto N, Komatsu Y.
    Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer.
    Support Care Cancer; 30(6):5351-5359. 2022.
  25. Kawamoto Y, Yuki S, Sawada K, Nakamura M, Muto O, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Meguro T, Harada K, Sekiguchi M, Okada K, Ito YM, Sakata Y, Sakamoto N, Komatsu Y.
    Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
    Oncologist; 27(8):e642-e649. 2022.
  26. Sakai SA, Aoshima M, Sawada K, Horasawa S, Yoshikawa A, Fujisawa T, Kadowaki S, Denda T, Matsuhashi N, Yasui H, Goto M, Yamazaki K, Komatsu Y, Nakanishi R, Nakamura Y, Bando H, Hamaya Y, Kageyama SI, Yoshino T, Tsuchihara K, Yamashita R.
    Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversities.
    Front Cell Infect Microbiol; 12:925444. 2022.
  27. Kadota T, Sato D, Inaba A, Nishihara K, Takashima K, Nakajo K, Yukami H, Mishima S, Sawada K, Kotani D, Fujiwara H, Nakamura M, Hojo H, Yoda Y, Kojima T, Fujita T, Yano T.
    Long-term clinical outcomes of patients diagnosed with pT1a-muscularis mucosae with lymphovascular invasion or pT1b after endoscopic resection for cT1N0M0 esophageal squamous cell carcinoma.
    Esophagus; 19:153-162. 2022.
  28. Nakamura M, Ishiguro A, Dazai M, Kawamoto Y, Yuki S, Sogabe S, Hosokawa A, Sawada K, Muto O, Izawa N, Nakashima K, Horie Y, Yagisawa M, Kajiura S, Ando T, Mitsuhashi Y, Sunakawa Y, Kikuchi Y, Komatsu Y.
    Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study.
    BMC Cancer; 22:1322. 2022.
  29. Harada K, Yamamura T, Muto O, Nakamura M, Sogabe S, Sawada K, Nakano S, Yagisawa M, Muranaka T, Dazai M, Tateyama M, Kobayashi Y, Kato S, Hatanaka K, Kawamoto Y, Yuki S, Sakata Y, Sakamoto N, Komatsu Y.
    Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101).
    J Clin Med; 12:1596. 2023.
  30. Nakatsumi H, Komatsu Y, Harada K, Kawamoto Y, Yuki S, Sawada K, Ishiguro A, Sogabe S, Ando T, Sasaki Y, Yoshikawa A, Nakamura M, Dazai M, Tateyama M, Muto O, Kotaka M, Sagawa T, Muranaka T, Hatanaka K, Takagi R, Sakata Y.
    A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801.
    Int J Cancer; 155:2223-2231. 2024.
  31. Bando H, Yamaguchi K, Mitani S, Sawada K, Mishima S, Komine K, Okugawa Y, Hosoda W, Ebi H.
    Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition.
    Cancer Sci; 115:1014-1021. 2024.
  32. Sakai D, Kadowaki S, Kawabata R, Hara H, Satake H, Takahashi M, Takeno A, Imai H, Minashi K, Kawakami T, Boku S, Matsuyama J, Sakamoto Y, Sawada K, Kataoka M, Kawakami H, Shimokawa T, Boku N, Satoh T.
    Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.
    J Clin Oncol. 43(19):2196-2207. 2025.
  33. Imai M, Nakamura Y, Shin S, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Sawada K, Sato A, Kuwata T, Yamashita R, Fujisawa T, Bando H, Ock CY, Fujii S, Yoshino T.
    Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial.
    JCO Precis Oncol; 9:e2400385. 2025.
  34. Okazawa-Sakai M, Sakai SA, Hyodo I, Horasawa S, Sawada K, Fujisawa T, Yamamoto Y, Boku S, Hayasaki Y, Isobe M, Shintani D, Hasegawa K, Egawa-Takata T, Ito K, Ihira K, Watari H, Takehara K, Yagi H, Kato K, Chiyoda T, Harano K, Nakamura Y, Yamashita R, Yoshino T, Aoki D.
    Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.
    J Gynecol Oncol; 36:e38. 2025.
  35. Kawamoto Y, Sawada K, Harada K, Motoo I, Ando T, Sogabe S, Kobayashi Y, Dazai M, Nakamura M, Hatanaka K, Ishiguro A, Sato A, Nakano S, Shindo Y, Hosokawa A, Ito K, Yoshikawa A, Ueda A, Iuchi K, Yokota I, Yuki S, Komatsu Y.
    A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).
    Gastric Cancer; 29(4):808-815. 2026.
  36. Ebata Y, Oki E, Hu Q, Hasuda H, Kawazoe T, Nambara S, Tsuda Y, Nakanoko T, Ando K, Kimura Y, Sawada K, Yamashita R, Horasawa S, Fujisawa T, Bando H, Nakamura Y, Yoshino T, Yokota H, Ohno H, Yoshizumi T.
    Gut microbiota diversity in patients with ESCC: associations with esophagectomy, the tumor immune microenvironment, and nivolumab response.
    Esophagus. doi: 10.1007/s10388-026-01205-3. 2026.
  37. Iwabuchi S, Sawada K, Kojima M, Ozawa M, Taniguchi H, Bando H, Abe K, Kuze Y, Imamura K, Kashima Y, Hirohashi Y, Tajima A, Torigoe T, Suzuki Y, Yoshino T, Hashimoto S.
    Single-Cell Analysis Identified a Recurrent Malignant-Associated Transcriptional State in Colorectal Cancer.
    Cancer Sci; 117(5):1397-1411. 2026.
  38. Harada K, Kajiura S, Sawada K, Hatanaka K, Sato A, Ito K, Tamura H, Doi A, Ando T, Nakamura M, Nakatsumi H, Muranaka T, Sogabe S, Ishii T, Nakano S, Dazai M, Sasaki Y, Kawamoto Y, Yuki S, Sakata Y, Komatsu Y.
    Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201).
    Support Care Cancer; 34(3):221. 2026.
  39. Inaba A, Kadota T, Nishihara K, Sato D, Nakajo K, Yukami H, Mishima S, Sawada K, Kotani D, Fujiwara H, Nakamura M, Hojo H, Yoda Y, Kojima T, Fujita T, Yano T.
    Long-term outcome after endoscopic submucosal dissection for entire circumferential cT1aN0M0 esophageal squamous cell carcinoma.
    Gastrointest Endosc: S0016-5107(26)00073-8. 2026.

著書

  1. 手足症候群のマネジメント（吉野孝之編：大腸癌に対するレゴラフェニブ治療，アークメディア，東京），2019
  2. HER2検査（日本臨床腫瘍学会編：大腸がん診療における遺伝子関連検査等のガイダンス第5版，金原出版，東京）2023
  3. 消化管がん薬物療法と腸内細菌の関係は？（佐竹悠良編：あらゆるCQに応える 消化管がん薬物療法マニュアル，南江堂，東京）2025
  4. ctDNA/MRD（室圭・上野誠編：オンコロジークリニカルガイド 消化器癌化学療法 改訂6版，南山堂，東京）2025
  5. HER2検査（日本臨床腫瘍学会編：大腸がん診療における遺伝子関連検査等のガイダンス第6版，金原出版，東京）2026
  6. HER2陽性大腸がんの治療開発，腫瘍内科，第23巻第6号，p596，2019
  7. Microbiome-based precision medicineの現状と展望，腫瘍内科，第27巻第6号，p697，2021
  8. マイクロバイオーム解析の臨床応用に向けた取り組み，腫瘍内科，第29巻第1号，p108，2022
  9. マイクロバイオームとがん治療，腫瘍内科，第29巻第6号，p736，2022
  10. MSS切除不能大腸癌のがん免疫療法の治療開発の課題と展望，癌と化学療法，50(11)，1175-1181，2023

国際学会

  1. Sawada K, Okamoto W, Nakamura Y, Yamanaka T, Yuki S, Yoshino T, Komatsu Y, Sakamoto N, Fujii S.
    Survival Outcome in HER2-amplified Metastatic Colorectal Cancer (mCRC).
    ASCO Gastrointestinal Cancers Symposium, San Francisco, 2018.
  2. Sawada K, Yamashita R, Horasawa S, Yoshikawa A, Fujisawa T, Nakamura Y, Taniguchi H, Hosokawa M, Kodama T, Kadowaki S, Kato K, Satoh T, Komatsu Y, Shiota M, Yasui H, Yamazaki K, Yoshino T.
    Gut microbiota and efficacy of immune-checkpoint inhibitors in patients with advanced solid tumor: SCRUM-Japan MONSTAR-SCREEN.
    ESMO congress, Paris, 2021.
  3. Sawada K, Nitta H, Nakamura Y, Okamoto W, Taniguchi H, Komatsu Y, Hara H, Kato T, Nishina T, Ohta T, Esaki T, Yoshino T, Fujii S.
    HER2 intratumoral genetic and non-genetic heterogeneity in metastatic colorectal cancer.
    ESMO congress, Paris, 2022.
  4. Sawada K, Nakano S, Kawamoto Y, Miyagishima T, Sogabe S, Ito K, Sato A, Yu C, Dazai M, Harada K, Yuki S, Yokota I, Komatsu Y.
    HGCSG1803：Single-arm phase II study evaluating efficacy of Oxaliplatin, Irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first line treatment.
    ESMO World Congress on Gastrointestinal Cancer, Barcelona, 2023.
  5. Sawada K, Kawamoto Y, Harada K, Ando T, Sogabe S, Kobayashi Y, Dazai M, Nakamura M, Hatanaka K, Ishiguro A, Sato A, Nakano S, Shindo Y, Hosokawa A, Ito K, Yoshikawa A, Iuchi K, Yokota I, Yuki S, Komatsu Y.
    Results of a phase 2 trial of ramucirumab plus docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).
    ASCO Gastrointestinal Cancers Symposium, San Francisco, 2025.